Literature DB >> 22346328

15th international congress of Parkinson's disease and movement disorders and inaugural melanoma and cutaneous malignancy meeting.

Walter Alexander.   

Abstract

Entities:  

Year:  2011        PMID： 22346328      PMCID： PMC3278142     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  6 in total

Review 1.  Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

Authors:  Simone Mocellin; Sandro Pasquali; Carlo R Rossi; Donato Nitti
Journal:  J Natl Cancer Inst       Date:  2010-02-23       Impact factor: 13.506

2.  A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series.

Authors:  Matthew C Foote; Bryan H Burmeister; Janine Thomas; B Mark Smithers
Journal:  Melanoma Res       Date:  2010-02       Impact factor: 3.599

3.  Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Authors:  Johan Hansson; Steinar Aamdal; Lars Bastholt; Yvonne Brandberg; Micaela Hernberg; Bo Nilsson; Ulrika Stierner; Hans von der Maase
Journal:  Lancet Oncol       Date:  2011-01-20       Impact factor: 41.316

4.  Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.

Authors:  Miki Shirakawa Garcia; Yoko Ono; Steve R Martinez; Steven L Chen; Heidi Goodarzi; Tiffany Phan; Lisa N Wehrli; Yoshinori Miyamura; Maxwell A Fung; Emanual Maverakis
Journal:  Melanoma Res       Date:  2011-06       Impact factor: 3.599

5.  Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.

Authors:  M J Mastrangelo; R E Bellet; J Berkelhammer; W H Clark
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

6.  Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.

Authors:  Axel Hauschild; Michael Weichenthal; Knuth Rass; Ruthild Linse; Carola Berking; Jörg Böttjer; Thomas Vogt; Konstanze Spieth; Thomas Eigentler; Norbert H Brockmeyer; Annette Stein; Helmut Näher; Dirk Schadendorf; Peter Mohr; Martin Kaatz; Michael Tronnier; Rüdiger Hein; Gerold Schuler; Friederike Egberts; Claus Garbe
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.